Web Exclusive: LIVESTRONG Goes Global
September 16, 2009 – Lacey Meyer
Web Exclusive: Hot Flashes: Q & A with Debra Barton, PhD
September 14, 2009 – Lacey Meyer
Web Exclusive: When is Multidisciplinary Care Really Needed?
September 21, 2009 – Debu Tripathy, MD
Web Exclusive: Quiz: Do You Know the Recommended Screening Guidelines?
September 22, 2009 – Lindsay Ray
Treatment Snapshot
September 16, 2009
Web Exclusive: How Are You DOING?
September 16, 2009 – Erik Ness
Web Exclusive: Itís Not Just Cancer
September 16, 2009 – Karen Patterson
Web Exclusive: Sexuality and Intimacy Resources
September 16, 2009 – Anna Sobering
Web Exclusive: Guidance on Guidelines
September 16, 2009 – Lindsay Ray
Web Exclusive: Fighting for Their Countrywomen
September 16, 2009 – Kathy LaTour
Web Exclusive: With Humor and Openness
September 16, 2009 – Charlcie Steuble
CYP2D6 Inhibitors
September 16, 2009
A Child's Grief
September 16, 2009 – Erik Ness
Connecting the World
September 16, 2009 – Kathy LaTour
Positively Speaking
September 16, 2009 – Nicole LeBrasseur, PhD
Tapping Broader Expertise
September 16, 2009 – Charlotte Huff
Sounds Like Teen Spirit
September 16, 2009
Screen Savers
September 16, 2009 – Laura Beil
Jumping into the Spirit
September 16, 2009 – Kathy LaTour
The Complete Eldercare Planner
September 16, 2009 – Kathy LaTour
www.cancerfac.org
September 16, 2009 – Anna Sobering
Donna Karan Changes the Design of Cancer Care
September 16, 2009 – Lindsay Ray
Kids Kick Cancer With Martial Arts and Karate Program
September 16, 2009 – Lacey Meyer
Q & A: Tamoxifen and Antidepressants
September 16, 2009 – Len Lichtenfeld, MD
Effective Strategy Found to Prevent Rash
September 16, 2009 – Lacey Meyer
News You Can Use: The Future of Breast Cancer Care
September 16, 2009
A Lion, An Angel, and a Pioneer
September 16, 2009 – Lacey Meyer
Big Tobacco, Meet the FDA
September 16, 2009 – Lacey Meyer
Deconstructing Grief
September 16, 2009 – Erik Ness
Breast Cancer Around the World
September 16, 2009 – Kathy LaTour
Prince & the Gun Oil
September 15, 2009 – Debra Jarvis
Teen Tribulations
September 16, 2009 – Marc Silver
Life Preserver?
September 16, 2009 – Laura Beil
Cancer Screening
September 16, 2009 – Barnett S. Kramer, MD
Kidney Cancer & Lung Cancer
September 16, 2009 – Elizabeth Whittington
I Laughed
September 16, 2009 – Krissy Dietrich Gallagher
Intestinal Insight
September 15, 2009 – Katy Human
How Should Ovarian Cancer Survivors Be Monitored for Relapse?
September 14, 2009 – Karen Patterson
Overheated
September 16, 2009 – Lacey Meyer
Letters from Our Readers
September 16, 2009
Message from the Editor
September 16, 2009 – Debu Tripathy, MD
Targeting the Triple Threat
September 10, 2009 – Nicole LeBrasseur, PhD
Meetings of the Minds
September 15, 2009 – Charlotte Huff
The Internal Flame
September 16, 2009 – Karen Patterson
Web Exclusive: LIVESTRONG Goes Global
September 16, 2009 – Lacey Meyer
Web Exclusive: Hot Flashes: Q & A with Debra Barton, PhD
September 14, 2009 – Lacey Meyer
Web Exclusive: When is Multidisciplinary Care Really Needed?
September 21, 2009 – Debu Tripathy, MD
Web Exclusive: Quiz: Do You Know the Recommended Screening Guidelines?
September 22, 2009 – Lindsay Ray
Treatment Snapshot
September 16, 2009
Web Exclusive: How Are You DOING?
September 16, 2009 – Erik Ness
Web Exclusive: Itís Not Just Cancer
September 16, 2009 – Karen Patterson
Web Exclusive: Sexuality and Intimacy Resources
September 16, 2009 – Anna Sobering
Web Exclusive: Guidance on Guidelines
September 16, 2009 – Lindsay Ray
Web Exclusive: Fighting for Their Countrywomen
September 16, 2009 – Kathy LaTour
Web Exclusive: With Humor and Openness
September 16, 2009 – Charlcie Steuble
CYP2D6 Inhibitors
September 16, 2009
A Child's Grief
September 16, 2009 – Erik Ness
Connecting the World
September 16, 2009 – Kathy LaTour
Positively Speaking
September 16, 2009 – Nicole LeBrasseur, PhD
Tapping Broader Expertise
September 16, 2009 – Charlotte Huff
Sounds Like Teen Spirit
September 16, 2009
Screen Savers
September 16, 2009 – Laura Beil
Jumping into the Spirit
September 16, 2009 – Kathy LaTour
The Complete Eldercare Planner
September 16, 2009 – Kathy LaTour
www.cancerfac.org
September 16, 2009 – Anna Sobering
Donna Karan Changes the Design of Cancer Care
September 16, 2009 – Lindsay Ray
Kids Kick Cancer With Martial Arts and Karate Program
September 16, 2009 – Lacey Meyer
Q & A: Tamoxifen and Antidepressants
September 16, 2009 – Len Lichtenfeld, MD
Effective Strategy Found to Prevent Rash
September 16, 2009 – Lacey Meyer
News You Can Use: The Future of Breast Cancer Care
September 16, 2009
A Lion, An Angel, and a Pioneer
September 16, 2009 – Lacey Meyer
Big Tobacco, Meet the FDA
September 16, 2009 – Lacey Meyer
Deconstructing Grief
September 16, 2009 – Erik Ness
Breast Cancer Around the World
September 16, 2009 – Kathy LaTour
Prince & the Gun Oil
September 15, 2009 – Debra Jarvis
Teen Tribulations
September 16, 2009 – Marc Silver
Life Preserver?
September 16, 2009 – Laura Beil
Cancer Screening
September 16, 2009 – Barnett S. Kramer, MD
Currently Viewing
Kidney Cancer & Lung Cancer
September 16, 2009 – Elizabeth Whittington
Intestinal Insight
September 15, 2009 – Katy Human
How Should Ovarian Cancer Survivors Be Monitored for Relapse?
September 14, 2009 – Karen Patterson
Overheated
September 16, 2009 – Lacey Meyer
Letters from Our Readers
September 16, 2009
Message from the Editor
September 16, 2009 – Debu Tripathy, MD
Targeting the Triple Threat
September 10, 2009 – Nicole LeBrasseur, PhD
Meetings of the Minds
September 15, 2009 – Charlotte Huff
The Internal Flame
September 16, 2009 – Karen Patterson

Kidney Cancer & Lung Cancer

New therapy available for renal cell carcinoma and first maintenance therapy is approved for lung cancer. 

BY Elizabeth Whittington
PUBLISHED September 16, 2009

The Food and Drug Administration approved Avastin (bevacizumab) in combination with interferon for metastatic renal cell carcinoma on July 31, adding to the arsenal of new drugs approved within the past few years for the relatively incurable cancer.   

Although there are approved drugs for the treatment of advanced nonsquamous cell non-small cell lung cancer (NSCLC), the approval of Alimta (pemetrexed) in early July marks the first drug available for maintenance therapy of advanced or metastatic disease.

The approval is based on a study presented at this year’s American Society of Clinical Oncology meeting that studied whether patients receiving Alimta after initial chemotherapy, but before disease progression, would benefit. The international phase III trial looked at more than 600 patients who successfully finished four cycles of platinum-based chemotherapy and were randomized to receive either Alimta or placebo. Alimta given every three weeks extended overall survival in patients with nonsquamous cell NSCLC by a median of five months when compared with placebo. However, patients with squamous cell NSCLC did not benefit from the drug, which means tumor histology (how the cells look under the microscope) can now be used to determine NSCLC treatment, a relatively new concept for treating the disease.

Alimta, first approved in 2004 for mesothelioma, is also approved as a first-line therapy for advanced NSCLC and for locally advanced or metastatic NSCLC after prior chemotherapy. Side effects of Alimta include fatigue, nausea, neuropathy, and rash. The drug is typically given with vitamin B12 to lessen side effects. For more information on Alimta, visit www.alimta.com (site is owned by Eli Lilly, the maker of Alimta). 

The approval came after results of the phase III AVOREN (Avastin in Renal) study showed nearly a five-month improvement in progression-free survival in patients taking the combination, compared with patients receiving interferon alone (10.2 months versus 5.4 months). Tumor size also decreased in 30 percent of patients taking Avastin, compared with 12 percent on interferon alone; however, no statistically significant improvement in overall survival was seen between the two groups (23 months in the Avastin arm versus 21 months in the interferon-only arm).

Avastin, a targeted drug that blocks the formation of new blood vessels to tumors, is also approved for advanced colorectal, lung, and breast cancers as well as certain brain cancers. Side effects of Avastin can include headache, constipation, and high blood pressure. Avastin also carries rare risks of perforations in the gastrointestinal tract, severe bleeding, and wound healing problems.

For more on kidney cancer, read “Reining in Renal Cancer” from the Summer 2009 issue at www.curetoday.com/reining_in_renal_cancer. For more information on Avastin, visit www.avastin.com (site is owned by Genentech, the maker of Avastin).

Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Kidney Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In